Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11753394 Synthesis of omecamtiv mecarbil

Patent 11753394 was granted and assigned to Amgen on September, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Amgen

Current Assignee

Amgen

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11753394

Patent Inventor Names

Andrew Cosbie

Archana Neergunda

Philipp C. Roosen

Kyle Quasdorf

Fang Wang

Bin Peter Quan

Lianxiu Guan

Xianqing Shi

...

Date of Patent

September 12, 2023

Patent Application Number

17324867

Date Filed

May 19, 2021

Patent Citations

‌

US Patent 8445495 Certain Chemical entities, compositions and methods

‌

US Patent 7507735 Compounds, compositions and methods

‌

US Patent 8101617 Disubstituted ureas and uses thereof in treating heart failure

‌

US Patent 8110595 Ureas and their use in the treatment of heart failure

‌

US Patent 9643925 Compounds, compositions and methods

‌

US Patent 9895308 Heterocyclic compounds and their uses

‌

US Patent 9951015 Heterocyclic compounds and their uses

‌

US Patent 9988354 Salt of omecamtiv mecarbil and process for preparing salt

...

Patent Primary Examiner

CPC Code

Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11753394 Synthesis of omecamtiv mecarbil

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API